Categories: CancerNews

Strategic Collaboration Formed Between Leo Cancer Care and Sumitomo Heavy Industries for Upright Proton Therapy

MIDDLETON, Wis., Sept. 26, 2025 /PRNewswire/ — Leo Cancer Care, a leader in innovative cancer care solutions, and Sumitomo Heavy Industries, a global pioneer in medical technology, have announced a strategic collaboration to introduce a new Proton Therapy configuration. This collaboration highlights both companies’ commitment to advancing the accessibility of proton therapy worldwide. The new configuration combines Sumitomo Heavy Industries’ latest compact cyclotron technology with Leo Cancer Care’s Marie® upright treatment solution including patient positioning and CT imaging.

While proton therapy has long been recognised for its precision in targeting tumors, widespread adoption has been hindered by the significant size, cost, and infrastructure requirements of conventional systems. Leo Cancer Care’s Marie upright proton therapy solution addresses these barriers by rotating the patient rather than the beam, meaning the technology is dramatically smaller and therefore more cost effective.

Upright proton therapy represents the biggest step forward in making proton therapy mainstream in a generation. Not only will it reduce the barriers of size and cost that have limited adoption for decades, growing research suggests remaining upright for treatment, our natural position, could support more consistent anatomical positioning while offering patients a more comfortable and connected patient experience.

Sumitomo Heavy Industries’ decision to embrace this approach marks a pivotal moment for the industry. While a growing number of vendors are adopting the Leo Cancer Care technology, Sumitomo Heavy Industries’ leadership and scale bring unique weight to the movement to innovating this much needed treatment option.

“This partnership with Sumitomo Heavy Industries is about more than technology, it’s about patients, for us it always is. By combining our upright solution with Sumitomo’s compact cyclotron, we’re taking a major step toward making proton therapy accessible to the many people who could benefit from it.”  “said Stephen Towe, CEO of Leo Cancer Care.

Toshikazu Hiasa, General Manager of the Industrial Equipment Division at Sumitomo Heavy Industries said “Through our technical collaboration with Leo Cancer Care, we aim to develop an optional feature enabling proton therapy in an upright position, in addition to our standard proton therapy system utilizing a rotating gantry. Achieving this will make proton therapy more accessible and patient-friendly, fulfilling our mission to enhance the quality and quantity of cancer treatment through medical accelerators.”

View original content:https://www.prnewswire.com/news-releases/strategic-collaboration-formed-between-leo-cancer-care-and-sumitomo-heavy-industries-for-upright-proton-therapy-302566018.html

SOURCE Leo Cancer Care

Staff

Recent Posts

Cheelcare Announces $1.0 Million Unsecured Note Financing

Markham, Ontario--(Newsfile Corp. - February 9, 2026) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the…

35 seconds ago

Optimi Health Completes MDMA Export for PTSD Treatment Under Australia’s Authorised Prescriber Scheme

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX:…

42 seconds ago

PureHealth Reports USD 550 Million Net Profit and Proposes USD 163 Million Dividend for FY 2025

USD 7.4 billion revenue and double-digit profit growth underline strength of Healthcare and Insurance across…

1 hour ago

Who is the Best Facelift Surgeon in Florida?

The Best Facelift Surgeon is Alberico J. Sessa, M.D in Florida SARASOTA, FL / ACCESS…

1 hour ago

Dr. Jonathan Spages Expands Diabetes Reversal Practice Across New States, Adds Clinical Team to Meet Growing Demand

TAMPA, FL / ACCESS Newswire / February 9, 2026 / Dr. Jonathan Spages, nationally recognized…

1 hour ago

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)…

4 hours ago